Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study

Helen C. Johnson*, Erin I. Lafferty, Rosalind M. Eggo, Karly Louie, Katherine Soldan, Jo Waller, W. John Edmunds

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)


Background Health equality is increasingly being considered alongside overall health gain when assessing public health interventions. However, the trade-off between the direct effects of vaccination and herd immunity could lead to unintuitive consequences for the distribution of disease burden within a population. We used a transmission dynamic model of human papillomavirus (HPV) to investigate the effect of ethnic disparities in vaccine and cervical screening uptake on inequality in disease incidence in England. Methods We developed an individual-based model of HPV transmission and disease, parameterising it with the latest data for sexual behaviour (from National Survey of Sexual Attitudes and Lifestyles [Natsal-3]) and vaccine and screening uptake by ethnicity (from Public Health England [PHE]) and fitting it to data for HPV prevalence (from ARTISTIC, PHE, Natsal-3) and HPV-related disease incidence (from National Cancer Registry [ONS]). The outcome of interest was the age-adjusted incidence of HPV-related cancer (both cervical and non-cervical) in all women in England in view of differences and changes in vaccination and screening uptake by ethnicity in England, over time. We also studied three potential public health interventions aimed at reducing inequality in HPV-related disease incidence: increasing uptake in black and Asian females to match that in whites for vaccination; cervical screening in women who turn 25 in 2018 or later; and cervical screening in all ages. Findings In the pre-vaccination era, before 2008, women from ethnic minorities in England reported a disproportionate share of cervical disease. Our model suggests that Asian women were 1·7 times (95% credibility interval [CI] 1·1–2·7) more likely to be diagnosed with cervical cancer than white women (22·8 vs 13·4 cases per 100 000 women). Because HPV vaccination uptake is lower in ethnic minorities, we predict an initial widening of this gap, with cervical cancer incidence in Asian women up to 2·5 times higher (95% CI 1·3–4·8) than in white women 20 years after vaccine introduction (corresponding to an additional 10·8 [95% CI 10·1–11·5] cases every year). In time, we predict that herd immunity benefits will diffuse from the larger white sub-population and the disparity will narrow. Increased cervical screening uptake in vaccinated women from ethnic minorities would lead to rapid improvement in equality with parity in incidence after 20 years of HPV vaccination. Interpretation Our study suggests that the introduction of HPV vaccination in England will initially widen a pre-existing disparity in the incidence of HPV-related cancer by ethnicity, partly due to herd immunity disproportionately benefiting subgroups with high vaccination rates. Although in time this induced disparity will narrow, increasing cervical screening uptake in girls from ethnic minorities should be encouraged to eliminate the inequality in cervical cancer incidence in the medium term. We recommend that dynamic effects should be considered when estimating the effect of public health programmes on equality. Funding Cancer Research UK.

Original languageEnglish
Pages (from-to)e44-e51
JournalThe Lancet Public Health
Issue number1
Publication statusPublished - Jan 2018

Bibliographical note

Funding Information:
This work was funded by Cancer Research UK (CA1655/A13254). We would like to thank the Natsal-3 and ARTISTIC teams for sharing their data and helping us to interpret it and the reviewers of the original manuscript for their strengthening comments. Natsal-3 is a collaboration between University College London, the London School of Hygiene & Tropical Medicine, NatCen social research, the Health Protection Agency, and the University of Manchester. The study was supported by grants from the Medical Research Council [G0701757]; and the Wellcome Trust [084840]; with contributions from the Economic and Social Research Council and Department of Health. We thank the study participants and the team of interviewers from NatCen social research who carried out the fieldwork. The Natsal study was approved by the Oxford Research Ethics Committee A (Ref: 10/H0604/27).


Dive into the research topics of 'Effect of HPV vaccination and cervical cancer screening in England by ethnicity: a modelling study'. Together they form a unique fingerprint.

Cite this